Drug data last refreshed 21h ago · AI intelligence enriched 1mo ago
IMODIUM MULTI-SYMPTOM RELIEF is a combination oral tablet containing loperamide hydrochloride (an antidiarrheal agent) and simethicone (an anti-gas agent) in chewable form. It is indicated for the symptomatic relief of diarrhea accompanied by gas, bloating, and cramping. The product works by slowing intestinal motility to reduce diarrhea while simethicone reduces gas-related discomfort.
As an OTC product approaching loss of exclusivity with moderate competitive pressure (30% intensity), commercial teams face revenue erosion and may shift focus to brand loyalty and line extension strategies.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on IMODIUM MULTI-SYMPTOM RELIEF offers experience in mature OTC brand management, retail partnership strategy, and defensive competitive positioning. Career trajectories lean toward commercial operations and consumer marketing rather than clinical or R&D advancement.
Worked on IMODIUM MULTI-SYMPTOM RELIEF at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.